Bayer Basket Study
21 Dec 2020
Trial Summary
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
Acronym:
–
ACTRN/NCT /ethics:
NCT03102320; Ethics# 127.17
Scientific title:
Phase 1b multi-indication study of anetumab ravtansine in mesothelin expressing advanced solid tumors (ARCS-Multi).
Sponsor / Cooperative group:
Bayer
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |